Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival

Cancer Immunology, Immunotherapy

Volumn 55, Issue 6, 2006, Pages 684-698

  Bellone, Graziella ^a   Smirne, Carlo ^a,b   Mauri, Francesco Angelo ^d   Tonel, Elena ^a   Carbone, Anna ^a,c   Buffolino, Alessandra ^a   Dughera, Luca ^c   Robecchi, Antonio ^a   Pirisi, Mario ^b   Emanuelli, Giorgio ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Cytokines; Pancreatic carcinoma; Tumor immunity

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; AGED; ARTICLE; CANCER IMMUNOLOGY; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CARCINOMA CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MICROENVIRONMENT; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; SERUM; SUPERNATANT; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644586895     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0047-0     Document Type: Article

References (64)

1. Alexandrakis MG, Passam FH, Pappa CA, Sfiridaki K, Tsirakis G, Damilakis J, Stathopoulos EN, Kyriakou DS (2004) Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res 28:259-266
2. Apte RN, Voronov E (2002) Interleukin-1 - a major pleiotropic cytokine in tumor-host interactions. Semin Cancer Biol 12:277-290
3. Barton BE (2001) IL-6-like cytokines and cancer cachexia: consequences of chronic inflammation. Immunol Res 23:41-58
4. Bellone G, Smirne C, Carbone A, Mareschi K, Dughera L, Farina EC, Alabiso O, Valente G, Emanuelli G, Rodeck U (2000) Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clin Cancer Res 6:2448-2455
5. Bellone G, Turletti A, Artusio E, Mareschi K, Carbone A, Tibaudi D, Robecchi A, Emanuelli G, Rodeck U (1999) Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155:537-547
6. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O (1991) Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164:1038-1042
7. Carbone A, Rodeck U, Mauri FA, Sozzi M, Gaspari F, Smirne C, Prati A, Addeo A, Novarino A, Robecchi A, Berretto O, Emanuelli E, Bellone G (2005) Human pancreatic carcinoma cells secrete bioactive Interleukin-18 after treatment with 5-Fluorouracil: Implications for anti-tumor immune response. Cancer Biol Ther 4:231-241
8. Cuny E, Loiseau H, Penchet G, Ellie E, Arsaut J, Vital A, Vincendeau P, Demotes-Mainard J (2002) Association of elevated glial expression of interleukin-1beta with improved survival in patients with glioblastomas multiforme. J Neurosurg 96:294-301
9. Dinarello CA (1998) Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 16:457-499
10. Fantuzzi G, Dinarello CA (1999) Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol 19:1-11
11. Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G, Gentilini O, Braga M (1996) Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 104:1-5
12. Ghayur T, Banerjee S, Hugunin M, Butler D, Herzog L, Carter A, Quintal L, Sekut L, Talanian R, Paskind M, Wong W, Kamen R, Tracey D, Allen H (1997) Caspase-1 processes IFN-inducing factor and regulates LPS-induced IFN- production. Nature 386:619-623
13. Goggins M, Shekher M, Turnacioglu K, Yeo CJ, Hruban RH, Kern SE (1998) Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58:5329-5332
14. Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, Uyemura K, Modlin R, Wollman J, Dubinett SM (1995) Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res 55:3847-3853
15. Kawabata T, Ichikura T, Majima T, Seki S, Chochi K, Takayama E, Hiraide H, Mochizuki H (2001) Preoperative serum interleukin-18 levels as a postoperative prognostic marker in patients with gastric carcinoma. Cancer 92:2050-2055
16. Kawakami Y, Okada T, Akada M (2004) Development of immunotherapy for pancreatic cancer. Pancreas 28:320-325
17. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D, Korc M (1999) The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18:5363-5372
18. Kruger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Huls C, Blankenstein T, Diamantstein T (1994) Expression of interleukin 10 in human melanoma. Br J Cancer 70:1182-1185
19. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics. CA Cancer J Clin 49:8-31
20. Lattime EC, McCue PA, Keely FX, Li W, Gomella LG (1995) Expression of IL-10 mRNA in biopsies of superficial and invasive TCC of the human bladder. Proc Am Assoc Cancer Res 36:462
21. Lawrence DA (1996) Transforming growth factor-beta: a general review. Eur Cytokine Netw 7:363-374
22. Lebel-Binay S, Thiounn N, De Pinieux G, Vieillefond A, Debre B, Bonnefoy JY, Fridman WH, Pages F (2003) IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer 106:827-835
23. Li A, Dubey S, Varney ML, Dave BJ, Singh RK (2003) IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 170:3369-3376
24. Ling P, Gately MK, Gubler U, Stern AS, Lin P, Hollfelder K, Su C, Pan YC, Hakimi J (1995) Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol 154:116-127
25. Lissoni P, Brivio F, Rovelli F, Fumagalli G, Malugani F, Vaghi M, Secondino S, Bucovec R, Gardani GS (2000) Serum concentrations of interleukin-18 in early and advanced cancer patients: enhanced secretion in metastatic disease. J Biol Regul Homeost Agents 14:275-277
26. Lu C, Kerbel RS (1993) Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120:1281-1288
27. MacKenzie MJ (2004) Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5:541-549
28. Maeda H, Shiraishi A (1996) TGF-beta contributes to the shift toward Th2-type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 156:73-78
29. Martone T, Bellone G, Pagano M, Beatrice F, Palonta F, Emanuelli G, Cortesina G (2004) Constitutive expression of interleukin-18 in head and neck squamous carcinoma cells. Head & Neck 26:494-503
30. Mattner F, Fischer S, Guckes S, Jin S, Kaulen H, Schmitt E, Rude E, Germann T (1993) The interleukin-12 subunit p40 specifically inhibits effects of the interleukin-12 heterodimer. Eur J Immunol 23:2202-2208
31. Michalaki V, Syrigos K, Charles P, Waxman J (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90:2312-2316
32. Moore MB, Kurago ZB, Fullenkamp CA, Lutz CT (2003) Squamous cell carcinoma cells differentially stimulate NK cell effector functions: the role of IL-18. Cancer Immunol Immunother 52:107-115
33. Nakagomi H, Pisa P, Pisa EK, Yamamoto Y, Halapi E, Backlin K, Juhlin C, Kiessling R (1995) Lack of interleukin-2 (IL-2) expression and selective expression of IL-10 mRNA in human renal cell carcinoma. Int J Cancer 63:366-371
34. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H (2001) Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev 12:53-72
35. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, Akita K, Namba M, Tanabe F, Konishi K, Fukuda S, Kurimoto M (1995) Cloning of a new cytokine that induces IFN- production by T cells. Nature 378:88-91
36. Pages F, Berger A, Henglein B, Piqueras B, Danel C, Zinzindohoue F, Thiounn N, Cugnenc PH, Fridman WH (1999) Modulation of interleukin-18 expression in human colon carcinoma: consequences for tumor immune surveillance. Int J Cancer 84:326-330
37. Paglia D, Oran A, Lu C, Kerbel RS, Sauder DN, McKenzie RC (1995) Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. J Interferon Cytokine Res 15:455-460
38. Park H, Byun D, Kim TS, Kim YI, Kang JS, Hahm ES, Kim SH, Lee WJ, Song HK, Yoon DY, Kang CJ, Lee C, Houh D, Kim H, Cho B, Kim Y, Yang YH, Min KH, Cho DH (2001) Enhanced IL-18 expression in common skin tumors. Immunol Lett 79:215-219
39. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:e36
40. Ramakers C, Ruijter JM, Deprez RH, Moorman AF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339:62-66
41. Rasmussen R (2001) Quantification on the LightCycler. In: Meuer S, Wittwer C, Nakagawara K (eds) Rapid Cycle Realtime PCR, Methods and Applications. Springer Press, Heidelberg, pp 21-34
42. Riedel F, Adam S, Feick P, Haas S, Gotte K, Hormann K (2004) Mannheim Alcohol Study Group. Expression of IL-18 in patients with head and neck squamous cell carcinoma. Int J Mol Med 13:267-272
43. Saito H, Tsujitani S, Oka S, Kondo A, Ikeguchi M, Maeta M, Kaibara N (2000) An elevated serum level of transforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 20:4489-4493
44. Sato T, McCue P, Masuoka K, Salwen S, Lattime EC, Mastrangelo MJ, Berd D (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383-1390
45. Scupoli MT, Sartoris S, Tosi G, Ennas MG, Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine NR, Scarpa A, Accolla RS (1996) Expression of MHC class I and class II antigens in pancreatic adenocarcinomas. Tissue Antigens 48:301-311
46. Seddighzadeh M, Larsson P, Ulfgren AC, Onelov E, Berggren P, Tribukait B, Torstensson A, Norming U, Wijkstrom H, Linder S, Steineck G (2003) Low IL-1alpha expression in bladder cancer tissue and survival. Eur Urol 43:362-368
47. Sobin LH, Wittekind CL (2002) (eds) International Union Against Cancer (UICC): TNM classification of malignant tumors. John Wiley & Sons Inc New York, pp. 93-96
48. Sotiriou C, Lacroix M, Lespagnard L, Larsimont D, Paesmans M, Body JJ (2001) Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett 169:87-95
49. Sozen S, Coskun U, Sancak B, Bukan N, Gunel N, Tunc L, Bozkirli I (2004) Serum levels of interleukin-18 and nitrite + nitrate in renal cell carcinoma patients with different tumor stage and grade. Neoplasma 51:25-29
50. Terabe M, Park JM, Berzofsky JA (2004) Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol Immunother 53:79-85
51. Tohyama K, Yoshida Y, Ohashi K, Sano E, Kobayashi H, Endo K, Naruto M, Nakamura T (1992) Production of multiple growth factors by a newly established human thyroid carcinoma cell line. Jpn J Cancer Res 83:153-158
52. Torroella-Kouri M, Keith JC, Ivanova M, Lopez DM (2003) IL-11-induced reduction of C/EBP transcription factor binding may contribute to the IL-12 downregulation in tumor-bearing mice. Int J Oncol 22:439-448
53. Trepicchio WL, Bozza M, Pedneault G, Dorner AJ (1996) Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 157:3627-3634
54. Trinchieri G (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3:133-146
55. Tsuboi K, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Kato H, Kuwano H (2004) Serum interleukin-12 and interleukin-18 levels as a tumor marker in patients with esophageal carcinoma. Cancer Lett 205:207-214
56. Ueda T, Shimada E, Urakawa T (1994) Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29:423-429
57. Ungefroren H, Voss M, Jansen M, Roeder C, Henne-Bruns D, Kremer B, Kalthoff H (1998) Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res 58: 1741-1749
58. Ungefroren H, Voss M, Bernstorff WV, Schmid A, Kremer B, Kalthoff H (1999) Immunological escape mechanisms in pancreatic carcinoma. Ann N Y Acad Sci 880:243-251
59. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ (1999) Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125: 73-84
60. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne-Bruns D, Kremer B, Kalthoff H (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(Suppl): 925s-932s
61. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mezzanzanica D, Canevari S, Ferrini S (2002) Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer 98:873-878
62. Wakeman CJ, Martin IG, Robertson RW, Dobbs BR, Frizelle FA (2004) Pancreatic cancer: management and survival. ANZ J Surg 74:941-944
63. Xu J, Menezes J, Prasad U, Ahmad A (1999) Elevated serum levels of transforming growth factor beta1 in Epstein-Barr virus-associated nasopharyngeal carcinoma patients. Int J Cancer 84:396-399
64. Zhang B, Ma XT, Zheng GG, Li G, Rao Q, Wu KF (2003) Expression of IL-18 and its receptor in human leukemia cells. Leuk Res 27:813-822